Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer

Hua Qing Wang, Yangang Ren, Zheng Zi Qian, Kai Fu, Hui Lai Zhang, Wei Li, Yun Hou, Shi Yong Zhou, Xi Shan Hao, Cong Hua Xie

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) and to investigate the association of the status of KRAS gene mutation and epidermal growth factor receptor (EGFR) genotype with clinical outcome. Methods: Twenty-eight patients with advanced NSCLC were enrolled in this single center, uncontrolled pilot clinical study. All the patients developed drug resistance or disease progression after first-line chemotherapy of either a docetaxel + cisplatin regimen or a vinorelbine + cisplatin regimen and then received nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy. Eight cases were stage IIIB and 20 were stage IV. An i.v. dosage regimen of 200mg of nimotuzumab was given as a single dose, injected into the patient at days 1, 8 and 15; i.v. gemcitabine was injected at a dose of 1000mg/m 2 at days 1 and 8 and cisplatin (25mg/m 2 i.v.) at days 1, 2 and 3. Each patient received four or more therapeutic cycles. The efficacy and toxic reactions were evaluated, as well as time to progression and overall survival. Results: In total, 28 patients with advanced NSCLC received 101 therapeutic cycles. The mean cycle number was 3.6. Median time to progression was 4.9 (2.5-6.5) months; median overall survival and 1-year survival rate were 9.8 months and 48.5%, respectively. There was one case of complete response, six cases of partial response, 11 cases of stable disease and 10 cases of progressive disease. Response rate was 25%, and clinical benefit rate was 64.3%. Major toxic reactions were bone marrow suppression and gastrointestinal reaction. Only one patient developed grade I acneiform eruption. Conclusion: Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced NSCLC was active and well-tolerated in this setting. Patients with EGFR amplification and KRAS gene wild type had a better prognosis. Prospective, randomized, controlled, large-scale clinical studies are needed to confirm the results.

Original languageEnglish (US)
Pages (from-to)72-78
Number of pages7
JournalThoracic Cancer
Volume3
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Poisons
docetaxel
Acneiform Eruptions
erbB-1 Genes
Survival
Gene Amplification
nimotuzumab
Epidermal Growth Factor Receptor
Drug Resistance
Disease Progression
Survival Rate
Bone Marrow
Genotype

Keywords

  • Advanced non-small-cell lung cancer
  • Combined therapy
  • Nimotuzumab
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer. / Wang, Hua Qing; Ren, Yangang; Qian, Zheng Zi; Fu, Kai; Zhang, Hui Lai; Li, Wei; Hou, Yun; Zhou, Shi Yong; Hao, Xi Shan; Xie, Cong Hua.

In: Thoracic Cancer, Vol. 3, No. 1, 01.02.2012, p. 72-78.

Research output: Contribution to journalArticle

Wang, Hua Qing ; Ren, Yangang ; Qian, Zheng Zi ; Fu, Kai ; Zhang, Hui Lai ; Li, Wei ; Hou, Yun ; Zhou, Shi Yong ; Hao, Xi Shan ; Xie, Cong Hua. / Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer. In: Thoracic Cancer. 2012 ; Vol. 3, No. 1. pp. 72-78.
@article{e5a34aeb65bc4d73936cc00a3c660c20,
title = "Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer",
abstract = "Objective: To evaluate the efficacy and safety of nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) and to investigate the association of the status of KRAS gene mutation and epidermal growth factor receptor (EGFR) genotype with clinical outcome. Methods: Twenty-eight patients with advanced NSCLC were enrolled in this single center, uncontrolled pilot clinical study. All the patients developed drug resistance or disease progression after first-line chemotherapy of either a docetaxel + cisplatin regimen or a vinorelbine + cisplatin regimen and then received nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy. Eight cases were stage IIIB and 20 were stage IV. An i.v. dosage regimen of 200mg of nimotuzumab was given as a single dose, injected into the patient at days 1, 8 and 15; i.v. gemcitabine was injected at a dose of 1000mg/m 2 at days 1 and 8 and cisplatin (25mg/m 2 i.v.) at days 1, 2 and 3. Each patient received four or more therapeutic cycles. The efficacy and toxic reactions were evaluated, as well as time to progression and overall survival. Results: In total, 28 patients with advanced NSCLC received 101 therapeutic cycles. The mean cycle number was 3.6. Median time to progression was 4.9 (2.5-6.5) months; median overall survival and 1-year survival rate were 9.8 months and 48.5{\%}, respectively. There was one case of complete response, six cases of partial response, 11 cases of stable disease and 10 cases of progressive disease. Response rate was 25{\%}, and clinical benefit rate was 64.3{\%}. Major toxic reactions were bone marrow suppression and gastrointestinal reaction. Only one patient developed grade I acneiform eruption. Conclusion: Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced NSCLC was active and well-tolerated in this setting. Patients with EGFR amplification and KRAS gene wild type had a better prognosis. Prospective, randomized, controlled, large-scale clinical studies are needed to confirm the results.",
keywords = "Advanced non-small-cell lung cancer, Combined therapy, Nimotuzumab, Second-line chemotherapy",
author = "Wang, {Hua Qing} and Yangang Ren and Qian, {Zheng Zi} and Kai Fu and Zhang, {Hui Lai} and Wei Li and Yun Hou and Zhou, {Shi Yong} and Hao, {Xi Shan} and Xie, {Cong Hua}",
year = "2012",
month = "2",
day = "1",
doi = "10.1111/j.1759-7714.2011.00083.x",
language = "English (US)",
volume = "3",
pages = "72--78",
journal = "Thoracic Cancer",
issn = "1759-7706",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "1",

}

TY - JOUR

T1 - Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer

AU - Wang, Hua Qing

AU - Ren, Yangang

AU - Qian, Zheng Zi

AU - Fu, Kai

AU - Zhang, Hui Lai

AU - Li, Wei

AU - Hou, Yun

AU - Zhou, Shi Yong

AU - Hao, Xi Shan

AU - Xie, Cong Hua

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Objective: To evaluate the efficacy and safety of nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) and to investigate the association of the status of KRAS gene mutation and epidermal growth factor receptor (EGFR) genotype with clinical outcome. Methods: Twenty-eight patients with advanced NSCLC were enrolled in this single center, uncontrolled pilot clinical study. All the patients developed drug resistance or disease progression after first-line chemotherapy of either a docetaxel + cisplatin regimen or a vinorelbine + cisplatin regimen and then received nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy. Eight cases were stage IIIB and 20 were stage IV. An i.v. dosage regimen of 200mg of nimotuzumab was given as a single dose, injected into the patient at days 1, 8 and 15; i.v. gemcitabine was injected at a dose of 1000mg/m 2 at days 1 and 8 and cisplatin (25mg/m 2 i.v.) at days 1, 2 and 3. Each patient received four or more therapeutic cycles. The efficacy and toxic reactions were evaluated, as well as time to progression and overall survival. Results: In total, 28 patients with advanced NSCLC received 101 therapeutic cycles. The mean cycle number was 3.6. Median time to progression was 4.9 (2.5-6.5) months; median overall survival and 1-year survival rate were 9.8 months and 48.5%, respectively. There was one case of complete response, six cases of partial response, 11 cases of stable disease and 10 cases of progressive disease. Response rate was 25%, and clinical benefit rate was 64.3%. Major toxic reactions were bone marrow suppression and gastrointestinal reaction. Only one patient developed grade I acneiform eruption. Conclusion: Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced NSCLC was active and well-tolerated in this setting. Patients with EGFR amplification and KRAS gene wild type had a better prognosis. Prospective, randomized, controlled, large-scale clinical studies are needed to confirm the results.

AB - Objective: To evaluate the efficacy and safety of nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) and to investigate the association of the status of KRAS gene mutation and epidermal growth factor receptor (EGFR) genotype with clinical outcome. Methods: Twenty-eight patients with advanced NSCLC were enrolled in this single center, uncontrolled pilot clinical study. All the patients developed drug resistance or disease progression after first-line chemotherapy of either a docetaxel + cisplatin regimen or a vinorelbine + cisplatin regimen and then received nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy. Eight cases were stage IIIB and 20 were stage IV. An i.v. dosage regimen of 200mg of nimotuzumab was given as a single dose, injected into the patient at days 1, 8 and 15; i.v. gemcitabine was injected at a dose of 1000mg/m 2 at days 1 and 8 and cisplatin (25mg/m 2 i.v.) at days 1, 2 and 3. Each patient received four or more therapeutic cycles. The efficacy and toxic reactions were evaluated, as well as time to progression and overall survival. Results: In total, 28 patients with advanced NSCLC received 101 therapeutic cycles. The mean cycle number was 3.6. Median time to progression was 4.9 (2.5-6.5) months; median overall survival and 1-year survival rate were 9.8 months and 48.5%, respectively. There was one case of complete response, six cases of partial response, 11 cases of stable disease and 10 cases of progressive disease. Response rate was 25%, and clinical benefit rate was 64.3%. Major toxic reactions were bone marrow suppression and gastrointestinal reaction. Only one patient developed grade I acneiform eruption. Conclusion: Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced NSCLC was active and well-tolerated in this setting. Patients with EGFR amplification and KRAS gene wild type had a better prognosis. Prospective, randomized, controlled, large-scale clinical studies are needed to confirm the results.

KW - Advanced non-small-cell lung cancer

KW - Combined therapy

KW - Nimotuzumab

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84861394907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861394907&partnerID=8YFLogxK

U2 - 10.1111/j.1759-7714.2011.00083.x

DO - 10.1111/j.1759-7714.2011.00083.x

M3 - Article

C2 - 28920255

AN - SCOPUS:84861394907

VL - 3

SP - 72

EP - 78

JO - Thoracic Cancer

JF - Thoracic Cancer

SN - 1759-7706

IS - 1

ER -